Laurence Lodé, Audrey Ménard, Laurent Flet, Steven Richebourg, Marion Loirat, Marion Eveillard, Yannick Le Bris, Catherine Godon, Olivier Theisen, Anne-Laure Gagez, Guillaume Cartron, Thérèse Commes-Maerten, Bruno Villemagne, Odile Luycx, Pascal Godmer, Catherine Pellat-Deceunynck, Thierry Soussi, Marie C. Béné, Jacques Delaunay, Pierre Peterlin. Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. haematol [Internet]. 2018Mar.23 [cited 2024May2];103(4):e143-e146. Available from: https://haematologica.org/article/view/8429